A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation (AF), an irregular heart rhythm that increases the risk of stroke and other heart-related complications.
Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.
Since launching its program offering patients with non-valvular atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke and avoiding long-term use of blood thinners, the Vanderbilt Heart and Vascular Institute (VHVI) has consistently ranked among the top centers in the country for the implantation of left atrial appendage closure (LAAC) devices.
Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
The irregular heart rhythm atrial fibrillation increases the risk of death in patients in the intensive care unit.
Accessibility Tools